Ospedale Santa Maria Goretti Latina

At Ospedale Santa Maria Goretti Latina the cardiology unit is testing innovative approaches to improve outcomes after acute myocardial infarction, including strategies to protect coronary microcirculation and to limit atherosclerotic progression.

• Evaluation of late sodium current inhibition to preserve microvascular function after STEMI
• Impact of SGLT2 inhibitors on coronary plaque stability post‑PCI
• Optimizing proteinuria management in patients with cardiovascular‑renal overlap
• Comparative effectiveness of novel antithrombotic regimens in multivessel disease

The department currently runs 15 trials with 12 investigators, positioning the site as a hub for cardiovascular innovation in Italy.

Research at the hospital focuses on personalized therapies for blood‑related malignancies such as acute myeloid leukemia with FLT3 mutations and chronic myeloid leukemia in chronic phase, aiming to enhance survival while reducing treatment toxicity.

• Biomarker‑guided intensification for FLT3‑positive AML
• Front‑line nilotinib versus imatinib strategies in CML
• Combination immunotherapy for relapsed marginal zone lymphoma
• Assessment of gemtuzumab ozogamicin in AML consolidation

With a portfolio of hematology trials, the unit contributes to advancing care for patients across Europe.

The site investigates immune‑modulating treatments for conditions like IgA nephropathy and Hodgkin’s lymphoma, exploring ways to balance efficacy and safety in chronic disease management.

• Early corticosteroid therapy versus RAS blockade in IgAN
• SGLT2 inhibitor regimens to reduce proteinuria in renal disease
• Phase I/II study of atezolizumab combined with BEGEV for relapsed Hodgkin’s lymphoma
• Evaluation of novel checkpoint inhibitors in refractory lymphomas

The immunology program includes 15 active studies, supported by a multidisciplinary team of 12 investigators.

Oncology trials at the facility target solid and hematologic tumors, including breast cancer and acute lymphoblastic leukemia, to refine treatment sequencing and improve long‑term remission rates.

• Sequential versus concurrent chemotherapy and aromatase inhibitors in early breast cancer
• Chemo‑free ponatinib and blinatumomab regimen for Ph+ ALL
• MRD‑driven strategies for remission in ALL and AML
• Combination therapies to enhance progression‑free survival in marginal zone lymphoma

The cancer research program leverages 15 clinical investigations, fostering collaboration across European oncology networks.

Studies in metabolic health aim to assess the benefits of newer agents such as semaglutide and SGLT2 inhibitors for patients with type 2 diabetes mellitus, focusing on glycemic control and cardiovascular risk reduction.

• Non‑inferiority of semaglutide added to reduced‑dose insulin versus intensified insulin therapy
• Achievement of individualized HbA1c targets with different SGLT2i compounds
• Effect of SGLT2i on coronary atherosclerosis progression after myocardial infarction
• Safety and efficacy of glucagon‑like peptide‑1 receptor agonists in overweight diabetic patients

The metabolic research unit conducts 15 trials, contributing valuable data to global diabetes treatment guidelines.